753 related articles for article (PubMed ID: 30012206)
1. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
[TBL] [Abstract][Full Text] [Related]
2. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
[No Abstract] [Full Text] [Related]
3. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
4. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.
Mizuta H; Nakano E; Takahashi A; Koyama T; Namikawa K; Yamazaki N
Dermatol Ther; 2020 May; 33(3):e13321. PubMed ID: 32191382
[TBL] [Abstract][Full Text] [Related]
5. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.
Pacholczak-Madej R; Grela-Wojewoda A; Lompart J; Żuchowska-Vogelgesang B; Ziobro M
Prague Med Rep; 2022; 123(1):35-42. PubMed ID: 35248163
[TBL] [Abstract][Full Text] [Related]
6. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy.
Tan I; Malinzak M; Salama AKS
J Immunother Cancer; 2018 Jul; 6(1):77. PubMed ID: 30064495
[TBL] [Abstract][Full Text] [Related]
7. Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab.
Satzger I; Ivanyi P; Länger F; Kreipe HH; Schaper-Gerhardt K; Beutel G; Cornberg M; Gutzmer R
Eur J Cancer; 2018 Apr; 93():150-153. PubMed ID: 29472154
[No Abstract] [Full Text] [Related]
8. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
Holmes Z; Courtney A; Hiong A
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
[TBL] [Abstract][Full Text] [Related]
9. [Meningeal syndrome in a patient treated with a combination of immune checkpoint inhibitors for a metastatic melanoma].
Bello-Chavolla OY; Cortes-Arroyo JE; Vargas-Vazquez A; Quiroz-Compean F; Leal-Gutierrez G; Barragan-Dessavre M; Martinez-Samano JE
Rev Neurol; 2018 Oct; 67(7):279-280. PubMed ID: 30232801
[TBL] [Abstract][Full Text] [Related]
10. Seronegative autoimmune autonomic ganglionopathy from dual immune checkpoint inhibition in a patient with metastatic melanoma.
Gao CA; Weber UM; Peixoto AJ; Weiss SA
J Immunother Cancer; 2019 Oct; 7(1):262. PubMed ID: 31623673
[TBL] [Abstract][Full Text] [Related]
11. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
Azari AE; Stratton R; Singh A
Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
[No Abstract] [Full Text] [Related]
12. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
13. Autoimmune polyradiculitis due to combination immunotherapy with ipilimumab and nivolumab for the treatment of metastatic melanoma.
Lasocki A; Smith K
J Clin Neurosci; 2020 Apr; 74():240-241. PubMed ID: 31983645
[TBL] [Abstract][Full Text] [Related]
14. Dual checkpoint inhibitor-associated eosinophilic enteritis.
Yang J; Lagana SM; Saenger YM; Carvajal RD
J Immunother Cancer; 2019 Nov; 7(1):310. PubMed ID: 31730503
[TBL] [Abstract][Full Text] [Related]
15. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
Alnabulsi R; Hussain A; DeAngelis D
Orbit; 2018 Oct; 37(5):381-384. PubMed ID: 29381409
[TBL] [Abstract][Full Text] [Related]
16. Bullous pemphigoid induced by ipilimumab in a patient with metastatic malignant melanoma after unsuccessful treatment with nivolumab.
Kuwatsuka Y; Iwanaga A; Kuwatsuka S; Okubo Y; Murayama N; Ishii N; Hashimoto T; Utani A
J Dermatol; 2018 Jan; 45(1):e21-e22. PubMed ID: 28944534
[No Abstract] [Full Text] [Related]
17. Neurologic Complications: Effects of Ipilimumab and Nivolumab Therapy in Patients With Metastatic Melanoma.
Latchman J; Guastella A; Tofthagen C
Clin J Oncol Nurs; 2019 Aug; 23(4):355-358. PubMed ID: 31322610
[TBL] [Abstract][Full Text] [Related]
18. Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report.
Appelbaum J; Wells D; Hiatt JB; Steinbach G; Stewart FM; Thomas H; Nghiem P; Kapur RP; Thompson JA; Bhatia S
J Immunother Cancer; 2018 Aug; 6(1):82. PubMed ID: 30170630
[TBL] [Abstract][Full Text] [Related]
19. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
[TBL] [Abstract][Full Text] [Related]
20. Thymic hyperplasia following double immune checkpoint inhibitor therapy in two patients with stage IV melanoma.
Mencel J; Gargett T; Karanth N; Pokorny A; Brown MP; Charakidis M
Asia Pac J Clin Oncol; 2019 Dec; 15(6):383-386. PubMed ID: 31373116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
